Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › Alisertib

Alisertib

0 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of Alisertib

31 trials tracked of Alisertib: 1 in phase 3 or 4.

31Trials tracked
1Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 3 1 Phase 2 16 Phase 1 14
  1. Phase 3 Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma Completed
  2. Phase 2 Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer Completed
  3. Phase 2 Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's Lymphoma Completed
  4. Phase 2 Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia Completed
  5. Phase 2 Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma Completed
  6. Phase 2 Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer Completed
Show 25 more trials
  1. Phase 2 Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma Completed
  2. Phase 2 MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine Completed
  3. Phase 2 MLN8237 for Treatment of Participants With Ovarian, Fallopian Tube, or Peritoneal Carcinoma Completed
  4. Phase 2 Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML Completed
  5. Phase 2 A Phase 2 Trial of MLN8237 in Adult Participants With Acute Myelogenous Leukemia and High-Grade Myelodysplastic Syndrome Completed
  6. Phase 2 Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer Completed
  7. Phase 2 Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer Completed
  8. Phase 2 Alisertib in Treating Patients With Advanced or Metastatic Sarcoma Completed
  9. Phase 2 Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Completed
  10. Phase 2 Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC) Completed
  11. Phase 2 Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer Completed
  12. Phase 1 A Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Participants With Advanced Solid Tumors Completed
  13. Phase 1 A Study of Alisertib (MLN8237) in Adult East Asian Participants With Advanced Solid Tumors or Lymphomas Completed
  14. Phase 1 Mass Balance, Pharmacokinetics and Metabolism Study of Alisertib Completed
  15. Phase 1 Food Effect Study of Alisertib (MLN8237) in Participants With Advanced Solid Tumors or Lymphomas Completed
  16. Phase 1 Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer Completed
  17. Phase 1 Pharmacokinetics of Alisertib in Adults With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Function Completed
  18. Phase 1 A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies Completed
  19. Phase 1 A Phase 1 Study of Alisertib Participants With Advanced Solid Tumors Including Castration-Resistant Prostate Cancer Receiving a Standard Docetaxel Regimen Completed
  20. Phase 1 Safety, Tolerability and Pharmacokinetic (PK) of Concomitant Esomeprazole and Rifampin, and QT Study on Single and Multiple-doses of Alisertib Completed
  21. Phase 1 Study of MLN8237 in Participants With Advanced Hematological Malignancies Completed
  22. Phase 1 A Phase I Clinical and Pharmacodynamic Study of MLN8237, A Novel Aurora A Kinase Inhibitor, in Participants With Advanced Malignancies Completed
  23. Phase 1 Study of MLN8237 in Participants With Advanced Solid Tumors Completed
  24. Phase 1 A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Alisertib in Participants With Advanced Solid Tumors or Relapsed/Refractory Lymphoma Completed
  25. Phase 1 Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas Completed

Showing the 31 most-cited and recently-updated of 31 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
No published articles yet for this medication. Check back soon.